€1.4million contract with US firm for European Trial

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the signing of an agreement worth over €1.4 million to conduct a European wide Phase II study for a US based company.

The deal comes on the back of multiple significant contract signings for Venn this year and sees the Company expanding its US customer base. Including this contract, Venn has announced new business wins totaling €8m in the past six months. This volume of business represents a major step change for Venn and justifies the significant investment in personnel and infrastructure in the past 18 months. 

Speaking about the agreement, Venn CEO, Tony Richardson stated: "The recent project wins demonstrate that our strategy of expanding our core services, our locations and our teams is coming to fruition for us as a company, and for our shareholders and our stakeholders. We now have a solid book of profitable contracts and a healthy pipeline of opportunities, which gives us confidence that we will deliver further growth in 2015."


Venn Life Sciences Holdings Plc


Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Orla Mc Guinness, Marketing Manager


Tel: +594 694410116

Zeus Capital (Nominated Adviser and Broker)


Ross Andrews/Andrew Jones (Corporate Finance)

Tel: +44 (0)161 831 1512

Dominic Wilson (Institutional Sales)

Tel: +44 (0)20 7533 7721



Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44 (0)7980 541 893

Lianne Cawthorne

Mob: +44 (0)7584 391 303



Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.